source
- Alnylam shares tumble to $250 after cutting full-year revenue guidance for its TTR franchiseAlnylam Pharmaceuticals saw its share price slide to about $250 after the company lowered its full-year revenue outlook for its transthyretin (TTR) franchise. The guidance cut, announced in July, f…
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion, expanding siRNA portfolioMerck KGaA, the German science and technology conglomerate, announced an agreement to purchase UK‑based Silence Therapeutics. The deal is valued at about $1.3 billion and gives Merck access to Sil…